South Rampart Pharma has dosed the first patient in its Phase I multiple ascending dose (MAD) study of non-opioid investigational drug SRP-001 for relieving pain.

The MAD study is a continuation of a single ascending dose (SAD) study that enrolled a total of 40 patients.

Patients initially received a dose of 300mg, with subsequent dose increases to 600mg, 900mg, and 2,000mg in the SAD study.

No serious adverse events or changes in laboratory values, including a robust PK profile, were observed.

In the MAD study of two cohorts, healthy male and female volunteers will receive SRP-001 orally.

Cohort one will receive SRP-001 500mg once daily for five days while cohort two will be randomised into a 1:1 male-to-female ratio, including six active and two placebo groups.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Safety and tolerability are the primary endpoints. They will be determined using vital signs, laboratory safety tests, physical examinations, electrocardiograms, adverse events, and select PK/PD parameters.

Lotus Clinical Research chief scientific officer and founder Dr Neil Singla said: “SRP-001 has incredible promise as an efficacious NME analgesic that avoids the pernicious side effects of acetaminophen and NSAIDs.”

South Rampart Pharma plans to launch a Phase II proof-of-concept study once supportive data has been collected from the MAD study, which would assess SRP-001’s efficacy and safety in patients undergoing third molar extraction.

The trial will enrol 200 subjects in a double-blind, randomised, placebo- and comparator-controlled, multi-centre study.

For the earlier study designs for pain, South Rampart Pharma approached Lotus Clinical Research, which has expertise in designing pain studies in the US.